3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Colorectal Neoplasms
56
Stomach Neoplasms
27
Pancreatic Neoplasms
18
Rectal Neoplasms
16
Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Neoplasm Metastasis
11
Esophageal Squamous Cell Carcinoma
8
Esophageal Neoplasms
8
Colonic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Carcinoma, Hepatocellular
8
Adenocarcinoma
8
Head and Neck Neoplasms
7
Gastrointestinal Neoplasms
7
Biliary Tract Neoplasms
6
Adenocarcinoma Of Esophagus
6
Ovarian Neoplasms
5
Peritoneal Neoplasms
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Nasopharyngeal Carcinoma
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Transitional Cell
3
Carcinoma
3
Breast Neoplasms
3
Appendiceal Neoplasms
3
Locally Recurrent Rectal Cancer
2
Interventions
Cisplatin
4
atezolizumab
3
Nivolumab
3
Carboplatin
3
pembrolizumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
abemaciclib
2
Vemurafenib
2
Radiosurgery
2
Pemetrexed
2
Mitomycin
2
Fulvestrant
2
Drug Therapy
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
ribociclib
1
repotrectinib
1
relatlimab
1
relacorilant
1
pertuzumab
1
palbociclib
1
olaparib
1
lutetium Lu 177 dotatate
1
exemestane
1
enzalutamide
1
enfortumab vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms by Site
×
Fluorouracil
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled